TABLE 1.

Participant demographics and characteristics

	Lamivudine Bup/Nlx*N = 7	Didanosine Bup/Nlx N = 10	Didanosine control N = 10	Tenofovir Bup/Nlx N = 10	Tenofovir control N = 10
Age (years)	39 (2.6)†*	35 (2.5)	41 (3.0)	35 (2.4)	37 (3.0)
Weight (kg)	101.9 (4.9)	93 (9.0)	84.4 (4.8)	100.1 (7.1)	94.6 (7.4)
Buprenorphine (mg/day)	14.0 (1.0)	16	N/A	16	N/A
Female	2 [28.5%]	3 [30%]	4 [40%]	2 [20%]	6 [60%]
Race
African-American	7	9	7	10	8
Caucasian	—	1	3	—	2
Hispanic	—	—	—	—
Mixed	—	—	—	—
Substance use disorders:
Opioid dependence	5	9	0	7	—
Cocaine abuse	1	3	4	3	2
Cannabis abuse	—	1	1	1	—
Alcohol abuse	—	—	2	—	1
Injection drug use	2 [28.5%]	2 [20%]	0	0	0
Nicotine use
Packs/day	0.3 (0.1)	0.7 (0.2)	0.6 (0.2)	0.4 (0.1)	0.2 (0.1)
Hepatitis C positive	1 [14%]	1 [10%]	0	1 [10%]	0
AST pre/post	25.4 (4.8)/	20.1 (1.9)/	22.3 (1.9)/	23.5 (3.7)/	27.8 (2.4)/
Normal range: 0-35 U/L	25.1 (5.2)	10.7 (2.3)	18.6 (2.1)	26.5 (4.2)‡	21.6 (1.8)§
ALT pre/post	23.3 (4.4)/	19.4 (3.1)/	21.7 (3.2)/	22.5 (4.7)∥	30.7 (4.3)/
Normal range: 0-35 U/L	24.6 (5.3)	18.6 (2.9)	20.0 (4.2)	24.9 (4.9)	23.1 (2.7)
Adverse symptoms	2.0 (1.1)/	7.4 (2.7)/	1.5 (1.2)/	2.4 (0.9)/	1.9 (1.1)/
Pre/post	2.6 (1.2)	5.1 (2.2)	0.6 (0.4)	3.2 (1.0)	1.8 (1.3)

^*Buprenorphine/naloxone maintenance treatment.

^†mean (SE).

[ ] percent of sample affected.

^‡p = .057.

^§p = .005.

^∥p = .054.